Compare Amphastar Pharmaceuticals Inc (AMPH) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Avalanche Treasury Corporation Class A Common Stock trades at $0.52 (market cap $21.30M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 38.8× Avalanche Treasury Corporation Class A Common Stock's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| AMPH | AVAT | |
|---|---|---|
Market Cap | $826.08M | $21.30M |
Sector | Health | Financials |
52-Week High | $30.81 | $10.75 |
52-Week Low | $16.87 | $0.51 |
Enterprise Value | $1.22B | $21.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
AVAT trades at $0.54, down 6.9% in the past 24 hours, with a bearish technical signal driven by moving averages. The company reported a net income of $8.28 million for 2025, but cash flow from operations was negative $930,710. Recent news highlights its Nasdaq listing, positioning it as an operating company focused on capital allocation within its ecosystem.
The outlook is mixed: low P/E of 12 and P/B of 0.4 suggest potential value, but negative operating cash flow and a bearish technical trend pose risks. Investor sentiment is cautious amid recent volatility, with institutional interest pending further financial stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
